A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC

"Drug:~Drug: SHR-1826 Administration by intravenous infusion for a cycle of 3 weeks.~Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks.~Drug: SHR-8068 Administration by intravenous infusion for a cycle of 6 weeks.~Drug: Bevacizumab Administration by intravenous infusion for a cycle of 3 weeks."